Alpha Tau Medical's CFO Signals Caution Amidst Soaring Stock and Clinical Hype

Related Articles

What is MY.Alpha Management's Latest Investment Strategy

3 months ago

Is AXTI's Recent Surge Sustainable Amidst AI Hype

3 months ago

Is the FinTech ETF (FINX) a Buy Amidst Economic Headwinds and AI Hype

2 months ago

What Does the New CFO Appointment Mean for GCDT

3 weeks ago

Category

You may also like

Stock News•3 weeks ago

CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing

CEO sold 34K shares of the oncology device firm for ~$615K, per SEC filing. The insider sale may signal reduced conviction or routine portfolio management.

NVCR

Share

Stock News•1 months ago

Agenus: Weighing The Clinical Progress Against The Company's Cash

Agenus faces a critical evaluation of its clinical development pipeline relative to its current cash position. Investors are weighing the company's ongoing research progress against the potential need...

AGEN

Share

Stock News•1 months ago

Alphatec - Slower Growth Seems Priced In Here

Alphatec shares have fallen two-thirds YTD as Q1 2026 revenue growth slowed to 14% at $192.1M. The company lowered its full-year sales guidance, reflecting decelerating momentum and persistent losses ...

ATEC

Share

Stock News•1 months ago

Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally

Alpha Tau Medical (NASDAQ:DRTS) shares rose Monday following the release of positive interim results from its U.S. clinical trial. The data evaluates the efficacy of Alpha DaRT in treating patients di...

DRTS

Share